American Cyanamid's paclitaxel
Hauser signs exclusive worldwide multiyear commercialization contract to supply bulk semi-synthetic paclitaxel, currently marketed in finished form as Bristol-Myers Squibb's Taxol, to American Cyanamid in return for an initial $1 mil. payment, the companies announce May 13. American Cyanamid subsidiary Immunex will develop and market paclitaxel for the U.S. and Canada, and Lederle will be responsible outside of North America. Cyanamid and Hauser also will collaborate in the research and development of new taxane analogs
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth